When was NTxBio founded?

NTxBio was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is NTxBio located?

NTxBio is headquartered in Santa Fe, United States.

How many employees does NTxBio have?

As of Jun 30, 2026, the latest employee count at NTxBio is 31.

Is NTxBio a funded company?

NTxBio is a funded company, having raised a total of $85.1M across 10 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Aug 15, 2018.

When was the latest funding round of NTxBio?

NTxBio's latest funding was a $***** Series B round on Nov 19, 2025, with participation from 0 investor. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $2.61B in funding in 2026 to date.

Where does NTxBio rank among its competitors?

NTxBio ranks 2nd amongst 52 active competitors, of which 21 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Kvantify, which secured $8.12M in Mar, 2026.

Who are the top competitors of NTxBio?

NTxBio's top competitors include Enveda, Kvantify and Vandria. Among them, Kvantify secured the most recent funding round in March, 2026.

NTxBio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of bio informatics platform to develops biologics and therapeutics. The company offers NTxscribe and NTxpress technologies that enable high-throughput screening and fast prototyping of novel biological materials with defined qualities. NTxscribe delivers high quality, high integrity conventional mRNA and long saRNA compatible for use with modified nucleotides. In addition to cell-free production, NTx offers real-time metabolic profiling of bacteria, fungi, and plants to discover, characterize and ultimately produce new chemical entities (NCEs) and biosimilars.

Website: ntxbio.com
Email ID: *****@ntxbio.com

Key Metrics

Founded Year

2016

Location

Santa Fe, United States

Stage

Series B

Total Funding

$85.1M in 10 rounds

Latest Funding Round

Series B, Nov 19, 2025, $*****

Investors

RA Capital Management & 6 more

Ranked

2^nd among 52 active competitors

Employee Count

31 as on Jun 30, 2026

Similar Companies

Enveda & 56 more

View NTxBio's full profile

NTxBio has raised a total funding of $85.1M over 10 rounds. Its first funding round was on Aug 15, 2018. NTxBio has 7 institutional investors.

Here is the list of recent funding rounds of NTxBio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 19, 2025	1913401	Series B	8262408	3746121	6736348	2650371
May 09, 2025	1015878	Series B	7366287	6127502	4102708	8962010
Dec 04, 2024	3298564	Venture Debt	1069778	8358409	1579953	J P Morgan

Access funding benchmarks and valuations. Sign up today!

View details of NTxBio's funding rounds and investors

The founders of NTxBio is Alexander Koglin.

Here are the details of NTxBio's key team members:

Alexander Koglin: Co-Founder of NTxBio.

View details of NTxBio's Founder profiles and Board Members

NTxBio's employee count trend

NTxBio has 31 employees as of Jun 26. Here is NTxBio's employee count trend over the years:

Uncover NTxBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NTxBio include Enveda, Kvantify and Vandria. Here is the list of Top 10 competitors of NTxBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Enveda 2019, Boulder (United States), Series D	AI-based platform to decipher the chemistry of nature and develop new medicines	$517M	Kinnevik, Premji Invest & 29 others	63/100
2nd	NTxBio 2016, Santa Fe (United States), Series B	Provider of bio informatics platform to develops biologics and therapeutics	$85.1M	RA Capital Management, Gates & 5 others	61/100
3rd	Kvantify 2022, Copenhagen (Denmark), Seed	Provider of quantum computing solutions for businesses in industries such as finance, life sciences, and logistics	$18.9M	Dreamcraft Ventures, Lundbeck Foundation ... & 10 others	61/100
4th	Vandria 2018, Lausanne (Switzerland), Series A	Developer of in-vitro screening platform for drug discovery and development	$30.7M	ND Capital, Dolby Family Ventures & 1 others	58/100
5th	Diagonal Therapeutics 2022, Cambridge (United States), Series B	Developer of antibody therapeutics for the treatment of rare diseases	$253M	VF Partners, Atlas Venture & 16 others	55/100
6th	QSimulate 2018, Cambridge (United States), Seed	Laboratory focused on developing of quantitative simulation tools to help in quantum molecular	$11M	2xN, Embark Ventures & 6 others	53/100
7th	revalia bio 2021, New Haven (United States), Seed	Provider of contract based drugs development services for biopharma sector	$26.8M	Sierra Ventures, Kidney & 4 others	53/100
8th	Redesign Science 2015, New York City (United States), Seed	Developer of protein-based small molecule drugs	$17M	Notation, Hangzhou Kaitai Capital Management ... & 10 others	44/100
9th	Helogen 2024, Mountain View (United States), Seed	Provider of space-based biomanufacturing and drug discovery services	-	One Way Ventures, Aum Ventures	44/100
10th	Progenra 2002, Malvern (United States), Series A	Developing innovative therapeutics targeting protein degradation for challenging diseases	$12M	Ben Franklin Technology Partners, HHS	43/100